Inovio Pharmaceuticals, Inc. (INO) is a publicly traded Healthcare sector company. As of May 21, 2026, INO trades at $1.26 with a market cap of $100.37M and a P/E ratio of -0.69. INO moved +2.46% today. Year to date, INO is -22.64%; over the trailing twelve months it is -42.25%. Its 52-week range spans $1.03 to $6.04. Analyst consensus is buy with an average price target of $4.50. Rallies surfaces INO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes INO SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $1.26 |
| Market Cap | $100.37M |
| P/E Ratio | -0.69 |
| EPS | $-1.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.04 |
| 52-Week Low | $1.03 |
| Volume | 704 |
| Avg Volume | 0 |
| Revenue (TTM) | $65.34K |
| Net Income | $-84.95M |
| Gross Margin | 0.00% |
2 analysts cover INO: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.50.